GSK Surges 8% After Bumping Its 2031 Outlook To North Of $50 Billion
GSK delivered a mixed fourth-quarter report Wednesday, but GSK stock surged on its long-term outlook for more than $50 ...
GSK Reported Strong Earnings, So I Reiterate My Strong Buy
GSK, a UK-based biopharma, reported strong 2024 results, with a promising shift toward specialty medicines. Read why I ...
GSK rises Wednesday, outperforms market
GSK PLC closed 18.56% below its 52-week high of £18.24, which the company reached on May 16th.
FiercePharma23h
With Blenrep's revival, GSK dials up long-term sales goal—again—despite RSV vaccine woes
Even as GSK’s RSV vaccine launch hits a serious slowdown, the British pharma has dialed up its long-term sales guidance once ...
FierceBiotech1d
GSK drops one potential 'functional cure' for hep B as it goes all-in on bepirovirsen
GSK is prioritizing development of its hepatitis B treatment bepirovirsen as the pharma ends work on another potential ...
GSK, gold miners shares push Britain's FTSE 100 higher
UK's FTSE 100 firmed on Wednesday after two straight days of losses, buoyed by gains in shares of heavyweight GSK and gold ...
GSK Expects Further Profit Growth After Beating Market Views
The pharmaceutical giant targets an increase in core operating profit of between 6% and 8% in 2025, after cancer treatments ...
BioSpace1d
GSK Looks to Deal in Cancer, Respiratory, Inflammation in 2025
Despite significant dips in its vaccines sales, the British pharma narrowly beat consensus estimates for Q4 2024 and raised ...
GSK tells Labour to back British firms after Astra bust-up
Chief executive Emma Walmsley said ministers must work with the sector to boost investment amid growing concerns about doing ...
GSK Shares Jump After Drugmaker Boosts Outlook, Positive Quarterly Results
American depositary shares of GSK jumped more than 8% Wednesday after the drugmaker reported better-than-expected quarterly results and boosted its long-term sales forecast. Sales of vaccines against ...